The flurry of moves Covidien plc (NYSE:COV) made in 2010 are starting to pay off for the Mansfield, Mass.-based medical products conglomerate.
New business from its $2.6 billion ev3 acquisition helped Covidien double its vascular unit’s sales during the three months ended March 25, posting revenues of $333 million, up 103 percent over the same period last year. And Covidien saw strong increases in sales of energy devices from the $250 million Somanetics buyout it consummated last July. That division reported a 17 percent increase over Q2 2010.
